Clinical Trial

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Study acronym: XER-001
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-28; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2026-02-06
Trial Details
NCT Number NCT07157033
Lead Sponsor Xerient Pharma
Conditions Locally Advanced Pancreatic Adenocarcinoma, Locally Advanced Pancreas Cancer, Locally Advanced Pancreatic Ductal Adenocarcinoma
Enrollment 36 participants
Start Date 2026-01-01
Primary Completion 2029-07-31 (estimated)
Study Completion 2034-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-01